MGTX MeiraGTx Holdings plc

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. The company was incorporated in 2015 and is based in New York, New York.

Date	Price Target	Rating	Analyst
7/31/2024	$36.00	Buy	Chardan Capital Markets

MeiraGTx Holdings plc

Peers

Recent Analyst Ratings for MeiraGTx Holdings plc

MeiraGTx Holdings plc SEC Filings

MeiraGTx Holdings plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

Amendment: SEC Form SCHEDULE 13G/A filed by MeiraGTx Holdings plc

SEC Form 10-Q filed by MeiraGTx Holdings plc

MeiraGTx Holdings plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

MeiraGTx Holdings plc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form DEFA14A filed by MeiraGTx Holdings plc

SEC Form DEF 14A filed by MeiraGTx Holdings plc

SEC Form 144 filed by MeiraGTx Holdings plc

MeiraGTx Holdings plc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement

SEC Form S-8 filed by MeiraGTx Holdings plc

MeiraGTx Holdings plc Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Yu Debra

SEC Form 4 filed by Director Shenk Thomas E

SEC Form 4 filed by Director Seligman Nicole

SEC Form 4 filed by Director Mendoza Neil

SEC Form 4 filed by Director Hukkelhoven Ellen

Amendment: SEC Form 4 filed by Director Harris Keith R.

SEC Form 4 filed by Director Harris Keith R.

SEC Form 4 filed by Director Perceptive Advisors Llc

Director Harris Keith R. converted options into 75,000 units of Ordinary Shares, increasing direct ownership by 150% to 125,000 units (SEC Form 4)

CFO & COO Giroux Richard sold $144,000 worth of Ordinary Shares (24,000 units at $6.00), decreasing direct ownership by 3% to 882,494 units (SEC Form 4)

MeiraGTx Holdings plc Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Perceptive Advisors Llc bought $5,000,000 worth of Ordinary Shares (1,250,000 units at $4.00) (SEC Form 4)

MeiraGTx Holdings plc Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Chardan Capital Markets resumed coverage on MeiraGTx with a new price target